AMNIOEXCEL® is an allograft, which is tissue that is transplanted from one person to another. Physicians use allografts in many ways and they have been used for decades to improve the lives of millions of patients. AMNIOEXCEL® is composed of a tissue that is retrieved from the amniotic sac of women who have chosen to donate this tissue after childbirth, which might otherwise be discarded.
AMNIOEXCEL® Patient Information/FAQs
The amniotic membrane is the innermost layer of the placenta. It lines the amniotic cavity which provides a protective environment for a developing embryo. It is a rich source of essential elements that can contribute to the natural reparative process of the human body.
Human amniotic membrane allografts have been used for many decades in surgical procedures and more recently in the treatment of difficult to heal wounds. Because of its natural healing properties, amniotic membranes are used to enhance the healing process of challenging wounds.
Yes. Over the years, processes have been developed that allow allograft tissues to be sterilized without significantly altering the natural properties that make them so beneficial. AMNIOEXCEL® is processed through a patent-pending technology called DryFlex®, which maintains its structure and properties but sterilizes the tissue to a level similar to any other sterile product used in the Operating Room today.
AMNIOEXCEL® is typically applied once every two weeks but this is at the discretion of your physician. At each dressing change, your physician will evaluate how well your wound is healing and may decide to apply another piece of AMNIOEXCEL® tissue before two weeks. Also, depending on the progression of your wound, your physician will decide when you can stop using AMNIOEXCEL®.
1. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, et al. Comprehensive foot examination and risk assessment: A report of the task force of the foot care interest group of the ADA, with endorsement by the AACE. Diabetes Care 2008; 8: 1679-1685. 2. Holzer SE, Camerota A, Marens L, et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 1998; 20:169-181. 3. Davis JW. Skin transplantation with a review of 550 cases at the Johns Hopkins Hospital. Johns Hopkins Med J. 1910; 15: 307-396. 4. Zelen CM, Serena TE et al. A prospective randomized comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J ISSN 1742-4801. 2013; June: 1-6. 5. Ueta M, Kweon M-N, Sano Y, Sotozono C, et al. Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction. Clin Exp Immun 2002; 129:464-470. 6. Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and anti-inflammatory proteins in human amniotic membrane. Cornea 2000; 19: 348-352. 7. Kjaergaard N, Hein M, Hyttel L, Helmig RB, Schonheyder HC, Uldbjerg N, Madsen H. Antibacterial properties of human amnion and chorion in vitro. Eur J Obst Gyn & Reprod Bio 2001; 94: 224-229. 8. Parolini O, et al. Human term placenta as a therapeutic agent: from the first clinical applications to future perspectives. In: Berven E, editor. Human placenta: structure and development. Hauppauge, New York: Nova Science Publishers, 2012: 1-48.
AMNIOEXCEL® and AMNIOMATRIX® are registered trademarks of BioD, LLC.